Interleukin‑1β weakens paclitaxel sensitivity through regulating autophagy in the non‑small cell lung cancer cell line A549

Lian,Juanwen; Hua,Tao; Xu,Jialing; Ding,Jie; Liu,Zejie; Fan,Yu

doi:10.3892/etm.2021.9724

Interleukin‑1β weakens paclitaxel sensitivity through regulating autophagy in the non‑small cell lung cancer cell line A549

Authors:
- Juanwen Lian
- Tao Hua
- Jialing Xu
- Jie Ding
- Zejie Liu
- Yu Fan
View Affiliations

Affiliations: Department of Oncology, Xi'an Chest Hospital, Xi'an, Shaanxi 710100, P.R. China
Published online on: January 27, 2021 https://doi.org/10.3892/etm.2021.9724
Article Number: 293
Copyright: © Lian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) poses a threat to human health and paclitaxel chemotherapy has been approved for the treatment of this type of cancer. However, resistance to treatment severely compromises the survival rate and prognosis of patients with NSCLC. The aim of the present study was to investigate the role of IL‑1β in paclitaxel sensitivity of NSCLC cells and elucidate the underlying mechanism. The expression of IL‑1β was found to be upregulated in NSCLC tissues and cells compared with healthy adjacent tissues and a normal epithelial cell line, respectively, as detected by reverse transcription‑quantitative PCR and western blot analyses. Subsequently, Cell Counting Kit‑8 assay and flow cytometry revealed that IL‑1β weakened the sensitivity of A549 cells to paclitaxel. It was subsequently demonstrated that IL‑1β induced A549 cell autophagy, while tunicamycin‑induced autophagy increased the IL‑1β expression level and weakened paclitaxel sensitivity. Thus, the results revealed that IL‑1β reduced the sensitivity to paclitaxel in A549 cells by promoting autophagy and suggested that IL‑1β may be of value for improving the therapeutic efficacy of paclitaxel chemotherapy in NSCLC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008.PubMed/NCBI View Article : Google Scholar
3	Rossi A and Di Maio M: Platinum-based chemotherapy in advanced non-small-cell lung cancer: Optimal number of treatment cycles. Expert Rev Anticancer Ther. 16:653–660. 2016.PubMed/NCBI View Article : Google Scholar
4	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018.PubMed/NCBI View Article : Google Scholar
5	Zhang D, Yang R, Wang S and Dong Z: Paclitaxel: New uses for an old drug. Drug Des Devel Ther. 8:279–284. 2014.PubMed/NCBI View Article : Google Scholar
6	Weaver BA: How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25:2677–2681. 2014.PubMed/NCBI View Article : Google Scholar
7	Ramalingam S and Belani CP: Paclitaxel for non-small cell lung cancer. Expert Opin Pharmacother. 5:1771–1780. 2004.PubMed/NCBI View Article : Google Scholar
8	Joshi M, Liu X and Belani CP: Taxanes, past, present, and future impact on non-small cell lung cancer. Anticancer Drugs. 25:571–583. 2014.PubMed/NCBI View Article : Google Scholar
9	Lu C, Xie Z and Peng Q: MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer. Am J Cancer Res. 7:1863–1873. 2017.PubMed/NCBI
10	Libby P: Interleukin-1 Beta as a target for atherosclerosis therapy: Biological basis of CANTOS and beyond. J Am Coll Cardiol. 70:2278–2289. 2017.PubMed/NCBI View Article : Google Scholar
11	Lopez-Castejon G and Brough D: Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 22:189–195. 2011.PubMed/NCBI View Article : Google Scholar
12	Arranz L, Arriero MDM and Villatoro A: Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications. Blood Rev. 31:306–317. 2017.PubMed/NCBI View Article : Google Scholar
13	Azad N, Rojanasakul Y and Vallyathan V: Inflammation and lung cancer: Roles of reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev. 11:1–15. 2008.PubMed/NCBI View Article : Google Scholar
14	Kim JW, Koh Y, Kim DW, Ahn YO, Kim TM, Han SW, Oh DY, Lee SH, Im SA, Kim TY, et al: Clinical implications of VEGF, TGF-β1, and IL-1β in patients with advanced non-small cell lung cancer. Cancer Res Treat. 45:325–333. 2013.PubMed/NCBI View Article : Google Scholar
15	Mendoza-Rodríguez MG, Ayala-Sumuano JT, García-Morales L, Zamudio-Meza H, Pérez-Yepez EA and Meza I: IL-1β inflammatory cytokine-induced TP63 isoform ∆NP63α signaling cascade contributes to cisplatin resistance in human breast cancer cells. Int J Mol Sci. 20(E270)2019.PubMed/NCBI View Article : Google Scholar
16	Feng X, Luo Q, Zhang H, Wang H, Chen W, Meng G and Chen F: The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma. J Exp Clin Cancer Res. 36(81)2017.PubMed/NCBI View Article : Google Scholar
17	Lee CR, Kang JA, Kim HE, Choi Y, Yang T and Park SG: Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance. FEBS Lett. 590:358–368. 2016.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	Yang X, Srivastava R, Howell SH and Bassham DC: Activation of autophagy by unfolded proteins during endoplasmic reticulum stress. Plant J. 85:83–95. 2016.PubMed/NCBI View Article : Google Scholar
20	Mendoza-Rodríguez M, Arévalo Romero H, Fuentes-Pananá EM, Ayala-Sumuano JT and Meza I: IL-1β induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells. Cancer Lett. 390:39–44. 2017.PubMed/NCBI View Article : Google Scholar
21	Bhat IA, Naykoo NA, Qasim I, Ganie FA, Yousuf Q, Bhat BA, Rasool R, Aziz SA and Shah ZA: Association of interleukin 1 beta (IL-1β) polymorphism with mRNA expression and risk of non small cell lung cancer. Meta Gene. 2:123–133. 2014.PubMed/NCBI View Article : Google Scholar
22	Lee CH, Chang JS, Syu SH, Wong TS, Chan JY, Tang YC, Yang ZP, Yang WC, Chen CT, Lu SC, et al: IL-1β promotes malignant transformation and tumor aggressiveness in oral cancer. J Cell Physiol. 230:875–884. 2015.PubMed/NCBI View Article : Google Scholar
23	Zhang Q, Wang H, Mao C, Sun M, Dominah G, Chen L and Zhuang Z: Fatty acid oxidation contributes to IL-1β secretion in M2 macrophages and promotes macrophage-mediated tumor cell migration. Mol Immunol. 94:27–35. 2018.PubMed/NCBI View Article : Google Scholar
24	Wang C, Wang MW, Tashiro S, Onodera S and Ikejima T: IL-1beta acts in synergy with endogenous IL-1beta in A375-S2 human melanoma cell apoptosis through mitochondrial pathway. J Korean Med Sci. 20:555–561. 2005.PubMed/NCBI View Article : Google Scholar
25	Guadagno J, Swan P, Shaikh R and Cregan SP: Microglia-derived IL-1β triggers p53-mediated cell cycle arrest and apoptosis in neural precursor cells. Cell Death Dis. 6(e1779)2015.PubMed/NCBI View Article : Google Scholar
26	Matanić D, Beg-Zec Z, Stojanović D, Matakorić N, Flego V and Milevoj-Ribić F: Cytokines in patients with lung cancer. Scand J Immunol. 57:173–178. 2003.PubMed/NCBI View Article : Google Scholar
27	Vikhreva P, Petrova V, Gokbulut T, Pestlikis I, Mancini M, Di Daniele N, Knight RA, Melino G and Amelio I: TAp73 upregulates IL-1β in cancer cells: Potential biomarker in lung and breast cancer? Biochem Biophys Res Commun. 482:498–505. 2017.PubMed/NCBI View Article : Google Scholar
28	d'Amato TA, Landreneau RJ, McKenna RJ, Santos RS and Parker RJ: Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer. Ann Thorac Surg. 81:440–446; discussion 446-447. 2006.PubMed/NCBI View Article : Google Scholar
29	Voloshin T, Alishekevitz D, Kaneti L, Miller V, Isakov E, Kaplanov I, Voronov E, Fremder E, Benhar M, Machluf M, et al: Blocking IL1β Pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Mol Cancer Ther. 14:1385–1394. 2015.PubMed/NCBI View Article : Google Scholar
30	Wong J, Tran LT, Magun EA, Magun BE and Wood LJ: Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: Synergistic effects of doxorubicin and vincristine. Cancer Biol Ther. 15:1395–1403. 2014.PubMed/NCBI View Article : Google Scholar
31	Parzych KR and Klionsky DJ: An overview of autophagy: Morphology, mechanism, and regulation. Antioxid Redox Signal. 20:460–473. 2014.PubMed/NCBI View Article : Google Scholar
32	Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell. 132:27–42. 2008.PubMed/NCBI View Article : Google Scholar
33	Tanida I and Waguri S: Measurement of autophagy in cells and tissues. Methods Mol Biol. 648:193–214. 2010.PubMed/NCBI View Article : Google Scholar
34	Harris J, Lang T, Thomas JPW, Sukkar MB, Nabar NR and Kehrl JH: Autophagy and inflammasomes. Mol Immunol. 86:10–15. 2017.PubMed/NCBI View Article : Google Scholar
35	Claude-Taupin A, Bissa B, Jia J, Gu Y and Deretic V: Role of autophagy in IL-1β export and release from cells. Semin Cell Dev Biol. 83:36–41. 2018.PubMed/NCBI View Article : Google Scholar
36	Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in cancer. Chin J Cancer. 36(52)2017.PubMed/NCBI View Article : Google Scholar
37	Kumar A, Singh UK and Chaudhary A: Targeting autophagy to overcome drug resistance in cancer therapy. Future Med Chem. 7:1535–1542. 2015.PubMed/NCBI View Article : Google Scholar
38	Liu S and Li X: Autophagy inhibition enhances sensitivity of endometrial carcinoma cells to paclitaxel. Int J Oncol. 46:2399–2408. 2015.PubMed/NCBI View Article : Google Scholar
39	Chen K and Shi W: Autophagy regulates resistance of non-small cell lung cancer cells to paclitaxel. Tumour Biol. 37:10539–10544. 2016.PubMed/NCBI View Article : Google Scholar
40	Wang Z, He R, Xia H, Wei Y and Wu S: Knockdown of STMN1 enhances osteosarcoma cell chemosensitivity through inhibition of autophagy. Oncol Lett. 13:3465–3470. 2017.PubMed/NCBI View Article : Google Scholar
41	Ran X, Yang J, Liu C, Zhou P, Xiao L and Zhang K: MiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy. Int J Clin Exp Pathol. 8:6617–6626. 2015.PubMed/NCBI